Live Breaking News & Updates on Director randall michael giuffre

Stay updated with breaking news from Director randall michael giuffre. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Sees Significant Increase in Short Interest

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Sees Significant Increase in Short Interest
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Randall-michael-giuffre , Dimensional-fund-advisors , Nasdaq , Renaissance-technologies , Citadel-advisors , Catalyst-financial-partners , Diamedica-therapeutics-inc , Securities-exchange-commission , Diamedica-therapeutics , Get-free-report , Director-randall-michael-giuffre , Exchange-commission

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Sees Significant Growth in Short Interest

DiaMedica Therapeutics Inc. (NASDAQ:DMAC – Get Free Report) was the target of a large growth in short interest in July. As of July 15th, there was short interest totalling 796,100 shares, a growth of 11.6% from the June 30th total of 713,600 shares. Approximately 4.5% of the shares of the stock are sold short. Based […] ....

Randall-michael-giuffre , Catalyst-financial-partners , Dimensional-fund-advisors , Nasdaq , Citadel-advisors , Renaissance-technologies , Diamedica-therapeutics-inc , Securities-exchange-commission , Diamedica-therapeutics , Get-free-report , Koch-thomas-von , Director-randall-michael-giuffre

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Director Purchases $254,150.00 in Stock

DiaMedica Therapeutics Inc. (NASDAQ:DMAC – Get Rating) Director Randall Michael Giuffre acquired 65,000 shares of DiaMedica Therapeutics stock in a transaction that occurred on Friday, June 23rd. The shares were bought at an average price of $3.91 per share, with a total value of $254,150.00. Following the transaction, the director now directly owns 360,355 shares […] ....

Randall-michael-giuffre , Diamedica-therapeutics-company-profile , Renaissance-technologies , Dimensional-fund-advisors , Nasdaq , Catalyst-financial-partners , Diamedica-therapeutics-inc , Citadel-advisors , Diamedica-therapeutics , Get-rating , Director-randall-michael-giuffre , Medica-therapeutics